Patients whose first biologic therapy is given as part of a clinical trial studying rheumatoid arthritis (RA) treatment

Patients who are receiving or have received experimental DMARDs as part of a clinical trial studying RA treatment in the last 12 months

Patients whose first biologic is rituximab, abatacept or anakinra.

Patients who have received any biologic therapy for more than 6 weeks prior to the inclusion visit

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis